Bookmark and Share

Namita Kundu Ph.D.

Academic Title: Assistant Professor
Primary Appointment: Pathology
Location: Bressler Research Building, 10-038
Phone: (410) 706-3322
Lab: (410) 706-5938

Personal History:

B.Sc (Honors), Chemistry, Calcutta University, Calcutta, India

M.Sc , Biochemistry, Calcutta University, Calcutta, India

Ph.D. Biochemistry, Calcutta University, Calcutta, India

Research Interests:

Breast cancer: tumor biology and metastasis, tumor immunology, cytokines, chemokines, cyclooxygenase, prostaglandin receptors


Sun, H., Jackson, M.J., Kundu, N. and Fulton, A.M. Interleukin-10 gene transfer activates IFN- and the IFN--inducible genes gbp-1/mag-1 and mig-1 in mammary tumors. International J. Cancer 80, 624-629 (1999).

Sun, H., Gutierrez, P., Jackson, M.J., Kundu, N. and Fulton, A.M. Essential role of nitric oxide and interferon- for tumor immunotherapy with interleukin-10. J. Immunother. 23, 208-214 (2000).

Sun, H., Kundu, N., Dorsey, R., Jackson, M.J. and Fulton, A. M. Expression of the chemokines IP-10 and Mig in IL-10 transduced tumors. J. Immunother. 24, 138-143 (2001).

Kundu, N., Yang, Q., Dorsey, R. and Fulton, A.M. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93, 681-686 (2001).

Kundu, N. and Fulton, A.M. Selective cyclooxygenase COX-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Can Res. 62(8), 2343-2346 (2002).

Dorsey, R., Kundu, N., Yang, Q., Tannenbaum, C.S., Sun, H., Hamilton, T.A. and Fulton, A.M. Immunotherapy with IL-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Can Res. 62(9), 2606-2610 (2002).

Kundu, N., Smyth, M.J., Samsel, L. and Fulton, A.M. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Research and Treatment 76, 57-64 (2002).

Ma,X., Yang, Q., Wilson, K.T., Kundu, N., Meltzer, S.J. and Fulton, A.M. Promoter methylation regulates cyclooxygenase expression in breast cancer. Breast Cancer Res. 6, R316-R321 (2004).

Kundu, N., Walser, T., Ma, X. and Fulton, A.M. Cyclooxygenase inhibitors modulates NK activities that control metastatic disease. Cancer Immunol. Immunother. 54, 981-987 (2005).

Ma, X., Kundu, N., Rifat, S., Walser, T. and Fulton, A.M. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 66:(6), 2923-2927 (2006). (Selected for cover and highlights section).

Walser, T.C., Rifat, S., Ma, X., Kundu, N., Ward, C., Goloubeva., Johnson, M.G.,Medina, J.C., Collins, T.L. and Fulton, A.M. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 66:(15),7701-7707 (2006).(Selected for highlights section).

Walser, T.C., Ma, X., Kundu, N., Dorsey, R., Goloubeva, O. and Fulton, A.M. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model: J. Immunother. 30, 490-498 (2007).